Drug Profile
Research programme: glycosylated taxoid derivatives - Kaken
Alternative Names: Glycosylated taxoid derivatives research programme - KakenLatest Information Update: 22 Mar 2007
Price :
$50
*
At a glance
- Originator Kaken Pharmaceutical
- Class
- Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 23 Jul 1999 This programme is available for licensing (http://www.kaken.co.jp)
- 23 Jul 1999 Preclinical development for Cancer in Japan (unspecified route)